Figure 2 | Gene Therapy

Figure 2

From: Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors

Figure 2

(a) Neutralizing antibody (NAb) titer against chimeric adenovirus (Ad5/3) was measured from the serum of 17 patients before and after the virus administration. Data are presented as a serum dilution factor causing 80% inhibition in gene transfer with Ad5/3luc1 to 293 cells. (b) Survival plot of 18 Ad5/3-Cox2L-D24-treated patients. Median survival of patients was 106.5 days.

Back to article page